Reference is made to the annual general meeting 18 May 2022 where a statement of remuneration to key personnel was given. In accordance with this statement the board of Gentian Diagnostics ASA has allocated a total of 219,996 options to key employees under the existing option program.
The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA:
Hilja Ibert, Chief Executive Officer: 80,000 options. Following the allocations Ms. Ibert holds 6,525 shares and 359,924 options
Njaal Kind, Group Chief Financial Officer: 19,996 options. Following the allocations Mr. Kind holds 21,125 shares and 175,666 options in the Company.
Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 40,000 options in the Company.
Jack Andreassen, Vice President Business Development: 10,000 options. Following the allocation Mr. Andreassen hold 4,385 shares and 32,500 options in the Company.
Markus Jaquemar, Vice President Sales and Marketing: 25,000 options. Following the allocation Mr. Jaquemar holds 47,500 options in the Company.
The exercise price for the options granted is NOK 46,67 being the average volume-weighted share price on the Oslo Stock Exchange from 1 January 2022 to 13 December 2022. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date (ii) 50% of the options granted, no earlier than 4 years after the allocation date.